BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Get Alerts BBIO Hot Sheet
Join SI Premium – FREE
PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019.
About BridgeBioBridgeBio a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
Media Contact:Grace Rauh[email protected](917) 232-5478
Source: BridgeBio Pharma, Inc.
Source: BridgeBio Pharma, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PCI Biotech Holding ASA - Annual Report 2023
- Umicore update on trading conditions over the first quarter of 2024
- Flash News: OKX Wallet Now Supports Reading of Staked STONE
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!